Niaid dmid big effect trial (BET) - initiate the management , oversight , and conduct of the niaid dmid clinical trial titled a multicenter platform evaluating putative therapeutics for the…
Ended Awarded Last action
- Contract number
- 75N91020F00011
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $47,810,387
Award facts
- Contract value 77% obligated
- $62,137,169.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Economy Act FAR subpart 17.5
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $22,000,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Definitize Letter Contract | $14,320,095 | |
| Original award | $11,490,292 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services' National Institutes of Health (NIH), awarded Leidos Biomedical Research, Inc. a $62.1 million cost-plus-fixed-fee delivery order contract to initiate management, oversight, and conduct of NIAID's DMID Clinical Trial titled "A Multicenter Platform Evaluating Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults" (short title). Under this contract, Leidos will manage and oversee NIAID's Big Effect Trial (BET) clinical study to evaluate potential treatments for COVID-19 in hospitalized adult patients. Work will be performed in Fort Detrick, Maryland through October 2023. As the prime contractor, Leidos will leverage its experience conducting large-scale infectious disease clinical research to help identify effective therapies aimed at reducing the burden of COVID-19.
Description
Niaid dmid big effect trial (BET) - initiate the management , oversight , and conduct of the niaid dmid clinical trial titled a multicenter platform evaluating putative therapeutics for the treatment of covid-19 in hospitalized adults (short title
Quick answers
Who was awarded contract 75N91020F00011?
75N91020F00011 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on May 1, 2020.
How much is contract 75N91020F00011 worth?
The government has obligated $47,810,387 on 75N91020F00011. Its current value, with exercised options, is $62,137,169.
Which agency awarded contract 75N91020F00011?
National Cancer Institute (National Institutes of Health) awarded 75N91020F00011, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91020F00011 an order under another contract?
Yes. 75N91020F00011 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00011 competed?
The extent of competition for 75N91020F00011 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award